Comparison of unfractionated heparin protocols using antifactor Xa monitoring or activated partial thrombin time monitoring (Reprinted from Journal of Health-System Pharmacy Residents JHPR, vol 1, issue 2, 2012)

被引:33
作者
Fruge, Kristian S. [1 ,3 ]
Lee, Young R. [2 ]
机构
[1] Our Lady Lake Reg Med Ctr, Baton Rouge, LA USA
[2] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Pharm Practice, Abilene, TX 79601 USA
[3] Hendrick Med Ctr, Abilene, TX USA
关键词
PARTIAL THROMBOPLASTIN TIME; WEIGHT; THERAPY; TRIAL; ASSAY; AGE;
D O I
10.2146/sp150016
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective. To determine whether there is a difference between an activated partial thromboplastin time (aPTT) based unfractionated heparin (UFH) protocol versus an antifactor Xa based UFH protocol with respect to 24-hour attainment of therapeutic levels. Methods. This was an observational study performed at a 500 bed private, community hospital. The study included inpatients from January 2008 to December 2009 on our institution's aPTT UFH protocol and inpatients from July 2010 to March 2011 on our institution's antifactor Xa UFH protocol. The two groups were compared to determine whether a higher percentage of patients reached therapeutic goal within 24 hours of UFH initiation. Secondary outcomes evaluated the percentage of patients at therapeutic goal within 6 and 12 hours, incidence of bleeding, and number of UFH dosage adjustments within 24 hours between the two groups. Results. One hundred twenty-one patients met inclusion criteria for this study; 79 in the aPTT group and 42 in the antifactor Xa group. At 24 hours, 74% of patients in the antifactor Xa group were at goal, versus 63% of patients in the aPTT group (p = 0.242). Nearly 57% of patients in the antifactor Xa group were at goal versus 27% in the aPTT group within 6 hours (p = 0.001). Subjects in the antifactor Xa group averaged 1.00 dosage adjustments per subject as compared to an 1.71 dosage adjustments per subject in the aPTT group within the first 24 hours (p = 0.003). Conclusion. The antifactor Xa assay should be used to monitor UFH versus aPTT due to less variability in measurements, the absence of a need for calibration with new reagents/coagulometers, quicker attainment of therapeutic levels, fewer dose adjustments, and similar bleeding rates.
引用
收藏
页码:S90 / S97
页数:8
相关论文
共 17 条
[1]   Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin [J].
Bates, SM ;
Weitz, JI ;
Johnston, M ;
Hirsh, J ;
Ginsberg, JS .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (03) :385-391
[2]   Problems with monitoring heparin anticoagulation [J].
Bussey, HI .
PHARMACOTHERAPY, 1999, 19 (01) :2-5
[3]  
FRUGE KS, 2012, JHPR, V1
[4]   Parenteral Anticoagulants Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].
Garcia, David A. ;
Baglin, Trevor P. ;
Weitz, Jeffrey I. ;
Samama, Meyer Michel .
CHEST, 2012, 141 (02) :E24S-E43S
[5]   Activated Partial Thromboplastin Time Versus Antifactor Xa Heparin Assay in Monitoring Unfractionated Heparin by Continuous Intravenous Infusion [J].
Guervil, David J. ;
Rosenberg, Amy F. ;
Winterstein, Almut G. ;
Harris, Neil S. ;
Johns, Thomas E. ;
Zumberg, Marc S. .
ANNALS OF PHARMACOTHERAPY, 2011, 45 (7-8) :861-868
[6]   Heparin and low-molecular-weight heparin - Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety [J].
Hirsh, J ;
Warkentin, TE ;
Raschke, R ;
Granger, C ;
Ohman, EM ;
Dalen, JE .
CHEST, 1998, 114 (05) :489S-510S
[7]   Antithrombotic therapy for venous thromboembolic disease [J].
Hyers, TM ;
Agnelli, G ;
Hull, RD ;
Weg, JG ;
Morris, TA ;
Samama, M ;
Tapson, V .
CHEST, 1998, 114 (05) :561S-578S
[8]   A RANDOMIZED TRIAL COMPARING ACTIVATED THROMBOPLASTIN TIME WITH HEPARIN ASSAY IN PATIENTS WITH ACUTE VENOUS THROMBOEMBOLISM REQUIRING LARGE DAILY DOSES OF HEPARIN [J].
LEVINE, MN ;
HIRSH, J ;
GENT, M ;
TURPIE, AG ;
CRUICKSHANK, M ;
WEITZ, J ;
ANDERSON, D ;
JOHNSON, M .
ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (01) :49-56
[9]   Substitution of a heparin correlation value for activated partial thromboplastin time in heparin nomograms [J].
Miller, Abigail E. ;
Montague, Deborah ;
Rodgers, Jo E. ;
Sanghvi, Sonali ;
Whinna, Herbert C. ;
Krumnacher, Heather .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (10) :893-898
[10]  
Olson JD, 1998, ARCH PATHOL LAB MED, V122, P782